Lake Forest, CA – Biodynamik Inc., an orthopedic medical technology company, has been selected as one of Southern California’s “Cool Companies” for 2025 by Connect, a leading capital platform that highlights high-growth startups poised to transform their industries.

Chosen from hundreds of applicants across the tech, life sciences, and consumer sectors, Biodynamik is one of only 11 life science companies to earn a spot in this year’s elite cohort. This recognition spotlights Biodynamik’s groundbreaking work in its FDA-cleared XT3 System.

“Being named a Cool Company is incredibly exciting because it shows that others are recognizing the potential we see every day,” said Johnny Chen, CEO of Biodynamik. “It’s a powerful validation of our team’s work.”

Since its inception, Connect’s Cool Companies program has facilitated over $900 million in Series A funding for alumni. As part of the 2025 class, Biodynamik will participate in exclusive investor showcases and capital matchmaking events, connecting with top venture firms seeking to accelerate next-generation healthcare solutions.

“We’re honored to join this powerful community of innovators,” said Shanbao Cheng, CTO of Biodynamik. “This recognition reflects the momentum behind our work as we begin treating patients and gather clinical evidence to showcase the real-world impact of our technology.”

To read more about this recognition, visit https://connect.org/class-of-2025-cool-companies/.

About Biodynamik

Biodynamik, Inc. develops orthopedic external fixation systems. The XT3® System is FDA 510(k) cleared for fracture fixation, nonunion, transverse bone transport of the tibia, and the correction of bony or soft tissue defects and deformities in adult patients. Biodynamik is sponsoring the SMILE-TTT study (IDE G260049) of transverse tibial transport in patients with diabetic foot ulcers; this use is investigational.